Daniel Kim, MD
Ophthalmology · Natchez, MSNPI 1346349727
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.6% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,008, 2.4 times the $416 reported in 2019.
Across 55 payments — averaging $49.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$450
- Biotissue Holdings Inc.$374
- Mallinckrodt Hospital Products Inc.$317
- Bausch & Lomb, A Division Of Bausch Health US, LLC$250
- Sun Pharmaceutical Industries Inc.$237
- AbbVie$187
- plus $917 from 14 others
What the payments were for
- Food & beverage$2,63897%
- Education$933%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 7 | $450 |
| Biotissue Holdings Inc. | 5 | $374 |
| Mallinckrodt Hospital Products Inc. | 3 | $317 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $250 |
| Sun Pharmaceutical Industries Inc. | 4 | $237 |
| AbbVie(2 entities) | 6 | $187 |
| Amgen(2 entities) | 3 | $145 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $123 |
| Glaukos Corporation | 1 | $108 |
| Bausch & Lomb Americas Inc. | 2 | $103 |
| Omeros Corporation | 1 | $71 |
| Novartis | 4 | $70 |
| Dompe US, Inc. | 2 | $65 |
| Aerie Pharmaceuticals, Inc. | 4 | $64 |
| Tarsus Pharmaceuticals, Inc. | 3 | $51 |
| Apellis Pharmaceuticals, Inc. | 1 | $48 |
| Shire North American Group Inc | 1 | $21 |
| Oyster Point Pharma, Inc. | 1 | $17 |
| Rayner Intraocular Lenses Limited | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$237
- ACTHAR$224
- BROMSITE$129
- XELPROS$129
- CEQUA$129
- TRYPTYR$120
- TEPEZZA$111
- KXL System$108
- Photrexa$108
- Voyager DSLT$100
How this compares
$2,731 in reported general payments places this provider in the 60th percentile of 150 ophthalmology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 83 | $59,237 |
| XiidraLifitegrast | 52 | $35,179 |
| RocklatanNetarsudil Mesylat/Latanoprost | 91 | $33,273 |
| CombiganBrimonidine Tartrate/Timolol | 52 | $19,912 |
| Latanoprost | 2,414 | $17,869 |
| LumiganBimatoprost | 35 | $17,674 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 75 | $17,360 |
| Brimonidine Tartrate | 438 | $15,804 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 91 | $13,039 |
| Cyclosporine | 39 | $12,163 |
| RhopressaNetarsudil Mesylate | 27 | $9,783 |
| Prednisolone Acetate | 218 | $9,694 |
| Restasis MultidoseCyclosporine | 14 | $8,731 |
| Timolol Maleate | 684 | $8,718 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 523 | $8,685 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Lumigan, Restasis Multidose, Alphagan P | $187 | $111,303195 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $64 | $43,056118 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $103 | $41,95769 claims |
| AlconSimbrinza | $450 | $17,36075 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 150 ophthalmology providers in Mississippi.
Other ophthalmology in Natchez
- Aaron SmithNatchez$3K
- Kiper NelsonHattiesburg$234K
- John ParkerTupelo$72K
- Joseph ChildsTupelo$42K
- Heather HancockJackson$39K
- Leslie AdenFlowood$38K
- Adam QuinnHattiesburg$29K
- Mark KoskoJackson$27K
- James ShippOxford$21K
- Calvin BrownOlive Branch$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.